ÃÛÌÒÊÓƵ

Try our Advanced Search for more refined results

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case overview

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

  1. February 01, 2024

    State-Led Generic Drug Cases Removed From MDL

    The Judicial Panel on Multidistrict Litigation has sent a trio of cases from state-level enforcers back to federal court in Connecticut, separating them from the sprawling MDL centralized in Pennsylvania over claims of price fixing in the generic drug industry.

  2. January 23, 2024

    3 Generic-Drug Cos. Reach Settlements In Price-Fixing MDL

    Generic-drug makers Apotex Corp., Heritage Pharmaceuticals Ltd. and Breckenridge Pharmaceutical Inc. have each agreed to shell out a combined $45 million to settle allegations they colluded to fix the prices of many medications, according to a trio of motions filed Tuesday in multidistrict litigation in Pennsylvania federal court.

  3. January 17, 2024

    Generic-Drug Cos. Say States Are Mum In MDL Discovery

    Generic-drug makers steeped in antitrust multidistrict litigation are asking for an order enforcing a months-old deadline for documents that most states have ignored, according to a memorandum filed in Pennsylvania federal court.

  4. December 07, 2023

    Generics Price-Fixing Cases Should Stay In MDL, Judge Says

    The Pennsylvania federal judge overseeing sprawling multidistrict litigation against generic-drug makers on Thursday told the U.S. Judicial Panel on Multidistrict Litigation that she does not recommend transferring state enforcer actions out of the MDL yet, saying there's more the court can do to get the cases ready for trial or to tee up settlement talks.

  5. November 02, 2023

    States Want Generic Drug Price-Fixing Claims Back In Conn.

    State enforcers accusing several generic drugmakers of price-fixing asked the Judicial Panel on Multidistrict Litigation to move their case back to Connecticut federal court, saying legislation signed by President Joe Biden last year spares state enforcers from the MDL process.

  6. October 04, 2023

    States Back Off Bid To Block Sandoz Spinoff In Antitrust Case

    Novartis AG completed the planned spinoff of its Sandoz unit on Wednesday, after state enforcers and others withdrew their bid to block the move over concerns about recovering alleged overcharges from a sprawling conspiracy to fix generic drug prices.

  7. September 29, 2023

    States Ask To Block Sandoz Spinoff Over Price-Fixing Claims

    State enforcers and others have asked a Pennsylvania federal court to halt Novartis AG's planned spinoff of its Sandoz unit, saying the move could stop them from recovering overcharges from the company for a sprawling conspiracy to fix generic drug prices.

  8. August 17, 2023

    DOJ Wants Equal Access To Docs in Ex-Exec's Criminal Case

    The U.S. Department of Justice has urged a Pennsylvania federal judge to deny a former Taro Pharmaceutical executive's bid to use material from multidistrict litigation over alleged generic drug price-fixing to defend himself in a related criminal case, arguing the request would create an unfair advantage since the court previously rejected a similar ask from the government.

  9. May 23, 2023

    DOJ, Drug Buyers Rip Teva's Criminal Probe Doc Bid In MDL

    The government and drug buyers fired back in separate filings in Pennsylvania federal court Tuesday against Teva's bid to use material from a criminal investigation into alleged generic drug price-fixing to defend itself in parallel civil multidistrict litigation over similar allegations, arguing it would undermine prosecutions and create a procedural "mess."

  10. March 20, 2023

    DOJ Defends Ask For Docs From Drug Price-Fixing MDL

    The U.S. Department of Justice defended its bid for discovery materials from multidistrict litigation over generic drug price-fixing claims for use in the government's related criminal prosecutions, rejecting the pharmaceutical companies' claims that the DOJ wanted "unfettered access."